IR vs ZYME · P/E 49, rev $7.24B vs rev $76.3M
Ingersoll Rand Inc (IR) versus Zymeworks Inc. Common Stock (ZYME) — a side-by-side from cached financials, not a winner call.
Ingersoll Rand Inc (IR) is a specialty industrial machinery company listed on US.
Zymeworks Inc. Common Stock (ZYME) is a biotechnology company listed on NASDAQ.
Latest reported IR revenue for 2024-12-31 was $7.24B. Net income was $846.3M. Revenue was up 5.2% from 2023-12-31 to 2024-12-31. IR currently screens at market cap $28.27B and trailing P/E 48.8.
Latest reported ZYME revenue for 2024-12-31 was $76.3M. Net income was -$122.7M. Revenue was up 0.4% from 2023-12-31 to 2024-12-31. ZYME currently screens at market cap $1.68B.
IR currently screens at market cap $28.27B and trailing P/E 48.8. ZYME currently screens at market cap $1.68B.
Not investment advice. Open the IR and ZYME stock pages for the full models.
Not investment advice.